Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVETAIL: DTG/3TC Dual Therapy vs DTG + TDF/3TC in HIV/TB Co-infected Patients
NCT06497465Phase 3Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Proportion with HIV-1 virologic suppression at 28 weeks. Started Sep 2025; status: recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06497465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497465.